CHD7 belongs to a family of nine mammalian chromodomain helicase DNA-binding domain (CHD) proteins, which share a unique combination of two N-terminal chromodomains and an Snf2 helicase-like ATPase domain, followed by DNA-binding domains (Woodage, Basrai, Baxevanis, Hieter, & Collins, 1997) . The most striking feature of this family of proteins is their ability to use the energy released from ATP hydrolysis to do mechanical work-like physically moving nucleosomes or bending DNAevents essential for chromatin templated processes. Non-redundant nucleosome/chromatin remodeling by CHD proteins has been demonstrated (Bouazoune & Kingston, 2012; Flaus & Owen-Hughes, 2001; Manning & Yusufzai, 2017) , thereby independently contributing to the dynamic modification of chromatin architecture and the control of diverse gene expression patterns in a cell type or tissue-specific manner. The condensation of DNA into tight chromatin represses gene expression by restricting access of transcription factors (TFs) and the core transcription machinery to DNA binding sites. In contrast, activation of gene expression requires altering the highly condensed heterochromatin into loosely packed euchromatin. Depending on the nature of the chromatin remodeler/chromatin remodeling complex, the chromatin structure can be modified in different ways: nucleosome sliding to unwrap a region that was previously blocked, nucleosome eviction to give free access to naked DNA, and histone exchange to create a variant nucleosome with altered DNA interacting properties (Becker & Workman, 2013) . Using biochemical assays Bouazoune and Kingston (2012) demonstrated that CHD7 has ATP-dependent nucleosome remodeling activity in the presence of extranucleosomal DNA. Furthermore, in an in vitro nucleosome mobilization assay, it was shown that CHD7 causes changes in nucleosome mobility comparable to SNF2H and closely related CHD8.
Together these results suggest that CHD7 preferentially "slides" the histone octamer to the center of the DNA fragment, and it can do so by associating with a short linker DNA unlike CHD8 that requires longer linkers. Together these experiments indicate that each of these closely related remodeling proteins have unique functions that may not be entirely compensated by the others (Bouazoune & Kingston, 2012; Manning & Yusufzai, 2017) . Additionally, investigation of CHARGE syndrome-associated CHD7 mutations showed subtle to complete loss of remodeling activity for mutant CHD7 proteins, strengthening the hypothesis that CHD7 haploinsufficiency is the underlying cause of CHARGE syndrome (Bouazoune & Kingston, 2012) . Genome-wide chromatin immunoprecipitation experiments have shown that in vivo CHD7 is preferentially found at distal gene-regulatory elements called enhancers that are marked by monomethylation of lysine 4 and acetylation of lysine 27 on histone 3 (Feng et al., 2017; Schnetz et al., 2009 ). Interestingly, with dynamic changes in gene expression during development, as rapidly changing sets of enhancers get activated, there is a simultaneous change in genomic regions bound by CHD7. Although genome wide targets of CHD7 in rapidly maturing human developmental cell populations remain to be determined, transient association of CHD7 at a handful of human NC specific enhancers was demonstrated in vitro (Bajpai et al., 2010) . Recent advances like assays for transposon accessible chromatin with sequencing (ATAC-seq) that help identify accessible DNA as well as nucleosome depletion from active enhancers have been used to understand the impact of CHD7 loss in model systems. Studies on neural progenitors have shown a reduction in DNA accessibility at tissue specific enhancers, in mouse models lacking CHD7 (Feng et al., 2017; Whittaker et al., 2017) , consistent with the idea that CHD7 is recruited to regulatory elements, where it evicts or displaces nucleosomes to activate enhancers in vivo. It remains to be seen if CHD7 is required for establishing or maintaining active NC enhancers.
3 | EVIDENCE SUPPORTING THAT CHARGE SYNDROME IS A NEUROCRISTOPATHY Some of the defining features of CHARGE syndrome are highly reminiscent of known neurocristopathies, which are syndromes or congenital defects that are caused by improper development of the NC. Therefore, we will first take a closer look at the development of this cell population and then analyze how this process may be affected by CHD7.
| NC development
NC cells are pluripotent cells with an exceptional migratory potential, which give rise to diverse derivatives including neurons, glia as well as cartilage, smooth muscle, and pigment cells. Evolutionarily, the NC is a vertebrate invention contributing to their defining features like the craniofacial skeleton and the paired sensory organs (Northcutt & Gans, 1983) . A schematic representation of the different stages of NC development is shown in Figure 1 . During development NC cells originate at the border region between the non-neural ectoderm and the neural ectoderm, which give rise to the epidermis or central nervous system, respectively. The induction of NC progenitors takes place at gastrula stages and involves a combination of signaling molecules including BMP, WNT, FGF, and retinoic acid. These signals lead to the activation of a gene regulatory network including neural plate border specifier genes like members of the Msx, Pax, and Zic families (Milet & Monsoro-Burq, 2012; Prasad et al., 2012; Stuhlmiller & García-Castro, 2012) . Subsequently NC specifier genes including Snail, FoxD3, and Sox9/ 10 are expressed, which regulate processes like the delamination, migration and differentiation of NC cells. In order to migrate, NC cells need to delaminate from the border of the neural plate and undergo a partial or complete epithelial-to-mesenchymal transition. The timing of delamination and EMT differs between species and axial level, and involves changes in cell polarity and cell adhesion properties (StroblMazzulla & Bronner, 2012; Theveneau & Mayor, 2012) . Members of the cadherin family of calcium-dependent cell adhesion molecules have been implicated as regulators of EMT and collective NC migration (Cousin, 2017; Taneyhill & Schiffmacher, 2017) . NC cells switch from the expression of characteristic epithelial cadherins to cadherins of a more mesenchymal character and replace tight junctions with gap junctions.
For example a switch from E-cadherin to N-Cadherin has been observed during EMT in Xenopus allowing NC cells to acquire a migratory phenotype (Scarpa et al., 2015) . Furthermore, the subtle switch in cadherin expression seems to be a prerequisite for the acquisition of contact inhibition of locomotion, a phenomenon whereby cells move
away from each other after cell-cell contact, and which contributes to directed NC cell migration (Stramer & Mayor, 2016 ). In summary, NC development involves different steps like induction, specification, delamination, migration and finally differentiation, which are controlled by a gene regulatory network. Disruption of NC development can take place at any of these steps and result in a variety of human diseases commonly known as neurocristopathies.
| CHARGE animal models
CHARGE syndrome is caused by heterozygous loss-of-function mutations in CHD7 (Vissers et al., 2004) , which allowed researchers to experimentally address the function of CHD7 in embryonic development. Vertebrate systems like the mouse, chick, zebrafish, and Xenopus, but also the invertebrate Drosophila, which lacks NC cells, have been analyzed and a number of animal models for the analysis of CHARGE syndrome has been established. We will first briefly introduce these models and then describe how these were used to demonstrate that CHARGE syndrome belongs to the neurocristopathies.
A Drosophila model for CHARGE syndrome has been developed using flies with reduced expression of the Drosophila homolog of CHD7, Kismet (Melicharek, Ramirez, Singh, Thompson, & Marenda, 2010) . The kismet gene was originally identified in a genetic screen for genes involved in the determination of segmental identity (Kennison & Tamkun, 1988) . Kismet is required for segmentation and segment identity (Daubresse et al., 1999) , but also plays a role in processes like retinal development and border cell migration (Mathieu, Sung, Pugieux, Soetaert, & Rorth, 2007; Melicharek et al., 2008) . Interestingly, border cells undergo a directed collective cell migration reminiscent of the migration of cranial NC cells. Concerning its signaling mechanism, Kismet has been implicated in Notch-, Ras-, canonical WNT-, and hedgehog signaling (Go & Artavanis-Tsakonas, 1998; Terriente-Félix, Molnar, Gómez-Skarmeta, & Celis, 2011; Therrien, Morrison, Wong, & Rubin, 2000; Thompson, Tremblay, Lin, & Bochar, 2008) . While null mutations in kismet are embryonic lethal, the partial knockdown of kismet in specific tissues using the Gal4/UAS system generated flies with similar symptoms as observed in CHARGE patients including defects in memory and motor function as well as eye development. Further, analysis of the developing central nervous system revealed axonal guidance and extension defects (Melicharek et al., 2010) . As the flies also showed defects in climbing behavior (indicating a requirement of kismet for the morphology and/or development of muscle cells), the authors suggest that this may also be consistent with the observed impaired motor coordination and musclerelated posture problems observed in CHARGE patients. Furthermore, Ghosh et al. (2014) showed that Kismet regulates glutamate receptor localization and synapse transmission at the neuromuscular junctions.
Thus, the Drosophila model provides the means to study the evolutionary conservation of CHD7 function and may be used to analyze distinct symptoms observed in CHARGE patients.
| EVIDENCE FOR A FUNCTION OF CHD7 IN NC DEVELOPMENT
The functional analysis of vertebrate CHD7 has significantly advanced our understanding of the molecular pathogenesis of CHARGE syndrome. Historically, most studies have used the mouse model system, but zebrafish and Xenopus data have also added significantly to the molecular understanding of CHD7 function. The temporal and spatial expression pattern of CHD7 supports its function in NC development. For example, mouse and Xenopus CHD7 are expressed in premigratory and migratory NC cells (Bajpai et al., 2010; Fujita, Ogawa, Kawawaki, & Ito, 2014) ; and chick CHD7 is expressed in the branchial arches, a structure to which NC cells are the major contributors (Aramaki et al., 2007) . In zebrafish, Chd7 FIGURE 1 Schematic timeline of NC development. Xenopus embryos are shown at stages of neural plate border formation, NC induction, specification, and migration. Nieuwkoop-Farber stages (below embryos) as well as expression of marker genes (above embryos) are indicated. Neural plate border and mandibular, hyoid, and branchial NC streams are depicted by different shades of blue. Anterior-posterior and dorsalventral axes are indicated, cg, cement gland; e, eye shows strong maternal expression and relatively ubiquitous expression throughout early embryogenesis. Later tissue-specific expression is detected in the brain, eyes, otic vesicle, and somites (Asad et al., 2016; Jacobs-McDaniels & Albertson, 2011; Patten et al., 2012) . In the mouse, CHD7 expression commences in NC derivatives like the inner ear, the cranial nerves, and the olfactory epithelium (Bosman et al., 2005) , and other tissues affected in CHARGE syndrome including the eye, kidney, gonads and the brain.
Considering that there are reviews in this issue addressing the role of CHD7 in heart, CNS, and inner ear development, we will focus here on its role in the development of the NC.
Loss-of-function data in various model systems have firmly established a role for CHD7 in NC development. While homozygous Chd7-mutant mice are embryonic lethal, Chd7 heterozygous mutant mice show variably penetrant defects in tissues affected in CHARGE syndrome like the eye, inner ear, heart, and craniofacial tissues (Bosman et al., 2005; Randall et al., 2009 ). These include cardiovascular malformations like septal defects of the heart and haemorrhages, choanal atresia, cleft palate, and genital abnormalities of the vulva, and (Bajpai et al., 2010) . Consistent with these data injection of Chd7
Morpholino oligonucleotides in zebrafish embryos resulted in a reduction, disorganization or even absence of cranial NC segments (Patten et al., 2012) , and a severe impairment of trunk NC cell migration (Asad et al., 2016) . Further, Morpholino-mediated knockdown caused a variety of defects in NC and NC-derived cell types including the craniofacial cartilage, cranial ganglia, enteric neurons, pigment cells, and myelinated Schwann cells (Asad et al., 2016) .
Recent findings indicate that CHD7 functions at specific stages of NC development. Using human NC-like cells as well as Xenopus embryos it was shown that CHD7 is essential to activate the transcriptional network including Sox9, Twist, and Snail2 required for NC migration and specification (Bajpai et al., 2010) . In contrast, at nearly 50% downregulation (mimicking CHD7 haploinsufficiency), NC border specifiers like Msx1, Zic1, or Pax3 (see Figure 1) were not affected. Together, these findings suggest that gene expression programs controlling NC migration are highly sensitive to Chd7 downregulation, while early induction events defining the neural plate border region occur normally in spite of partial loss of Chd7.
Interestingly, both downregulation of chd7 or overexpression of a dominant-negative chd7 construct in Xenopus recapitulated major features of CHARGE syndrome (examples are shown in Figure 2 ).
Xenopus embryos showed eye defects reminiscent of coloboma and heart defects, including mispositioning of the truncus arteriosus and the cardiac outflow tract. Further malformations of the craniofacial cartilage and missing or misplaced otoliths, structures analogous to the human ear, were frequently observed. Thus, these data provided the first experimental evidence that CHARGE syndrome is indeed a neurocristopathy.
The function of CHD7 in NC development is likely not limited to NC specification, but may also involve later steps like migration and differentiation. In zebrafish, Chd7 was shown to be crucial for the differentiation of pigment cells and myelinated Schwann cells (Asad et al., 2016) . Chd7 morphants showed defects in the migration of pigment precursors as well as in the differentiation of the pigment lineages. A role in NC migration is also supported by a genome-wide microarray expression analysis of wild-type and CHD7 deficient mouse embryos at the time of NC migration. Interestingly, this approach identified a large number of guidance and cell adhesion molecules which were differentially expressed between wild-type and CHD7 mutants. These included members of the semaphorin, Eph receptor, and cadherin families suggesting a role in NC cell migration (Schulz, Wehner, et al., 2014) . Consistent with this hypothesis, knockdown of chd7 in Xenopus led to a reduction in sema3a expression, one of the identified class 3 semaphorins which is known to be involved in Kallmann syndrome. A role for CHD7 in the epigenetic regulation of class 3 semaphorins was further supported by genome-wide transcriptional analysis of mice with conditional ablation of Chd7 in early cardiogenic mesoderm (Payne et al., 2015) . Aberrant expression was shown for members of the class 3 semaphorins as well as components of the Slit-Robo signaling pathway. Furthermore, CHD7 localization at the Sema3c promoter was demonstrated in vivo. Taken together, these data support a role of CHD7 in the epigenetic regulation of NC development at stages of specification as well as migration. However, it should be noted that not all CHARGE phenotypes can be explained by defects in NC development. Therefore, although we would place CHARGE syndrome amongst the common neurocristopathies, we acknowledge that some of the defects are likely not NC-based; on the other hand not all NC-derived cell types are affected, for example, CHARGE patients usually do not show pigmentation defects. Thus, we will refer the reader to further reviews in this special issue addressing the role of CHD7 in non-neural crest tissues.
| CHD7 PROTEIN COMPLEXES AND THEIR FUNCTION IN DEVELOPMENT AND DISEASE
Proteins involved in the mechanism of nucleosome remodeling are typically part of larger multiprotein complexes. Therefore, it is not surprising that a number of interacting partners have been described for CHD7. For example CHD7 cooperates in human NC-like cells with members of the polybromo-and BRG1-associated factor containing complex (BAF/PBAF), an ATP-dependent chromatin remodeling complex, to control gene expression important for NC cell development (Bajpai et al., 2010) . During mouse cardiovascular development, BRG1 is required for survival, differentiation and migration of mutipotent NC cells. BRG1 inhibits apoptosis by suppressing Ask1 (apoptosis signal-regulating kinase 1) and promotes proliferation of NC cells by inhibiting the cell cycle inhibitor p21 cip1 . Furthermore, BRG1
has been shown to cooperate with CHD7 to activate PlexinA2, a receptor for semaphorin guidance cues, which is required to direct NC cells to the cardiac outflow tract (Li et al., 2013) . Further interaction partners are other proteins involved in chromatin remodeling and important developmental pathways (Zentner et al., 2010) .
For some genetic diseases it has been shown that mutations in the causative genes as well as mutations in genes coding for their interacting proteins lead to clinically overlapping conditions. Consistently, CHARGE syndrome shows phenotypic overlap with other developmental disorders, which are summarized in Figure 3 . One of these is the Kabuki syndrome (OMIM 147920), which is characterized by a typical facial gestalt in combination with short stature, intellectual disability, skeletal findings, dermatoglyphic anomalies, and additional features like cardiac and urogenital malformations, cleft palate, hearing loss, and ophthalmological anomalies. Especially in young children the clinical distinction between CHARGE and Kabuki syndrome can be very challenging, because they lack the typical facial gestalt of Kabuki syndrome, but show organ malformations reminiscent of the FIGURE 3 CHARGE syndrome and related disorders. The figure depicts malformation disorders that show phenotypic overlap to CHARGE syndrome. The causative genes of these disorders as well as the molecular link to CHARGE syndrome are indicated. Treacher Collins syndrome is caused by mutations in the gene coding for the nucleolar protein TCOF1. An association with CHARGE syndrome was postulated via a p53 pathway hyperactivation and effects on rRNA synthesis. Different genes can be mutated in Kallmann syndrome including FGF8 as well as SEMA3A. A genetic link to CHARGE syndrome has been postulated, because Chd7 represses Fgf8 via an increased expression of Otx2, a strong repressor of Fgf8. Furthermore, SEMA3A expression is decreased in CHD7-deficient mouse embryos suggesting a regulatory loop. The genes which are mutated in Kabuki syndrome, are KMT2D, a histone H3 lysine 4 (H3K4) methyltransferase, and KDM6A, a lysine-specific histone demethylase. CHD7 can interact with methylated histone H3 at lysine 4 (H3K4me) via its chromodomains. KMT2D interacts with the proteins WDR5, ASH2L, and RbBP5 (WAR complex). CHD7 is associated with the WAR complex possibly via an interaction with CHD8, suggesting that CHD7, KMT2D, and KDM6A comprise the same nucleosome modifying and remodeling machinery. A common pathomechanism of CHARGE and 22q11.2 syndrome has not been elucidated yet. Possible links are SMAD and BMP signaling components, which may be shared CHD7 and TBX1 target genes. CHD7 is a transcriptional cofactor of SOX2, regulating target genes like JAG1 (Alagille syndrome), Mycn (Feingold syndrome), and Gli3 (Pallister-Hall syndrome) phenotypes observed for CHARGE syndrome. The genes which are mutated in Kabuki syndrome are KMT2D, a histone H3 lysine 4 (H3K4) methyltransferase (Li et al., 2011; Ng et al., 2010) , and KDM6A, a lysine-specific histone demethylase, that interacts with KMT2D (Lederer et al., 2012) . KMT2D is required for setting the active mark, H3K4 di-and trimethylation, while KDM6A removes the repressive mark, H3K27 trimethylation. CHD7 can interact with methylated histone H3 at lysine 4 (H3K4me) via its chromodomains and it is highly enriched in a subset of active enhancer elements with high levels of H3K4me (Schnetz et al., 2009 (Schnetz et al., , 2010 . KMT2D interacts with the proteins WDR5, ASH2L, and RbBP5, the so-called WAR complex. This complex represents a core unit which is able to activate the H3K4 methyltransferase by binding in close proximity to the catalytic SET domain (Ernst & Vakoc, 2012) . CHD8, another CHD member belonging to the same subgroup as CHD7, is capable of forming a complex with WDR5, ASH2L, and RbBP5 in the absence of KMT2D (Thompson et al., 2008; Yates, Menon, Thompson, & Bochar, 2010) . We demonstrated that CHD7 interacts with CHD8 (Batsukh et al., 2010) and that CHD7 is associated with members of the WAR complex suggesting that CHD7, KMT2D, and KDM6A work in the same nucleosome modifying and remodeling machinery, explaining the clinical overlap between CHARGE and Kabuki syndrome (Schulz, Freese, et al., 2014) .
22q11.2 deletion syndrome (OMIM 188400) is another condition with remarkable phenotypic overlap to CHARGE syndrome. The overlapping clinical features include congenital heart defects, cleft palate, ear abnormalities and deafness, short stature, developmental delay, renal abnormalities, immune defects, and hypocalcaemia (Corsten-Janssen et al., 2013) . Haploinsufficiency of TBX1, a T-box transcription factor, is thought to contribute to the 22q11.2 deletion phenotype. In mice double heterozygous for a Chd7 and Tbx1 mutation, a synergistic effect of CHD7 and TBX1 on the development of the fourth pharyngeal arch, thymus, and semicircular canals was described (Randall et al., 2009) . The authors hypothesized that CHD7 has an influence on TBX1 expression, but testing the expression at stages between E8.5 and E10.5 in embryos with heterozygous mutations at the other locus did not confirm this idea. An alternative hypothesis is that CHD7 and TBX1 are involved in the same developmental pathway sharing the same target genes (Basson & van Ravenswaaij-Arts, 2015) . It has been shown that TBX1 interacts with SMAD1, influences SMAD1 to SMAD4 binding and suppresses BMP4/SMAD1 signaling (Fulcoli, Huynh, Scambler, & Baldini, 2009 ).
Furthermore, CHD7 interacts with SMAD1 (Liu et al., 2014) .
Another possible link of CHARGE and 22q11.2 deletion syndrome could be via upregulated p53 signaling. Van Nostrand et al. (2014) observed that a knock-in mutant mouse strain with heterozygous expression of a stabilized and transcriptionally inactive variant of the tumor-suppressor protein p53 exhibits a phenotype typical for CHARGE syndrome. Furthermore, the authors showed that Chd7-null mouse NC cells and fibroblasts from patients with CHARGE syndrome have increased p53 signaling and that Chd7 binds to the p53 promotor to repress p53 gene expression (van Nostrand et al., 2014) .
Additional experiments show that p53 heterozygosity can partially rescue the phenotypes in CHD7-null mouse embryos (van Nostrand et al., 2014) . Interestingly, symptoms of Tbx1 deficiency can also be rescued by reduction of p53 levels (Caprio & Baldini, 2014) . In Treacher Collins syndrome (OMIM 154500), another congenital malformation disorder with craniofacial abnormalities caused by mutations in treacle (TCOF1), increased apoptosis and reduced proliferation of NC cells are caused by upregulation of p53. Conversely, inhibition of p53 rescues the craniofacial phenotype (Jones et al., 2008) . Further experiments are necessary to gain deeper insight into whether p53 inhibition is a successful tool to rescue or prevent neurocristopathies and congenital craniofacial malformations.
Co-localization between CHD7 and P300, OCT4, SOX2, NANOG, SMAD1, and STAT3 at enhancer elements was shown in murine embryonic stem cells (Schnetz et al., 2010) . Engelen et al. (2011) demonstrated that CHD7 is a SOX2 transcriptional cofactor. Furthermore, Engelen et al. (2011) These observed symptoms are thought to occur due to a migration defect of neuroendocrine GnRH cells and olfactory neurons from the olfactory placode toward the hypothalamus and bulbus olfactorius (Schwanzel-Fukuda, Bick, & Pfaff, 1989; Teixeira et al., 2010) . Because these are also common in CHARGE syndrome patients (Chalouhi et al., 2005; Ogata et al., 2006) it has been assumed that Kallmann syndrome -caused by CHD7 mutations-represents a mild allelic variant of CHARGE syndrome (Jongmans et al., 2009) For FGF8 and SEMA3A proteins a regulatory loop with CHD7 has been described (Basson, 2014; Schulz, Wehner, et al., 2014; Yu et al., 2013) .
Using mouse models, haploinsufficiency of Chd7 was reported to cause a reduced Fgf8 expression in the isthmus organizer, a signaling center important for cerebellar development (Yu et al., 2013) .
The Chd7 effect on the Fgf8 expression in the isthmus organizer was proposed to be tissue-specific and indirect via increased expression of the orthodenticle homeobox 2 (Otx2) gene, a strong repressor of Fgf8 (Basson, 2014; Yu et al., 2013) . By performing a genome-wide microarray expression analysis on wild-type and CHD7 deficient mouse embryos at embryonic day 9.5, we recently showed that reduced Chd7 expression led to a reduced Sema3a expression. The CHD7-SEMA3A regulatory loop was confirmed using the Xenopus PAULI ET AL. | 483 system, demonstrating the evolutionary conservation of this mechanism (Schulz, Wehner, et al., 2014) .
Taken together, these findings indicate that CHD7 has tissuespecific effects on the epigenetic regulation of transcription and guidance factors and thereby controls NC cell specification, migration and differentiation. In addition, distinct CHD7 interaction partners fine-tune the spatial and temporal activities of CHD7 function as well as target gene selection. Furthermore, these modular CHD7 multiprotein complexes may represent the molecular link between CHARGE and other syndromes with clinical overlapping phenotypes.
For example, the causative genes may be part of the same chromatin remodeling complex, controlling a set of common target genes. Recent studies have successfully used gene-specific DNA methylation signatures to identify common target genes (Butcher et al., 2017) and promise that the characterization of the epigenome in combination with functional studies will help us to elucidate the pathophysiology of CHARGE syndrome. 
